[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356388-105":59,"doc-detail-356388-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cdk46-inhibition-in-the-management-of-metastatic-hrher2-breast-cancer-systematic-review-and-meta-analysis","CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer - Systematic Review and Meta-analysis","","Hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer represents about 10% of cases and is linked to therapeutic resistance and heterogeneous clinical outcomes. This systematic review and descriptive meta-analysis synthesizes evidence from four clinical trials assessing CDK4/6 inhibitors combined with endocrine and anti-HER2 therapy in metastatic HR+/HER2+ disease. A random-effects model summarizes pooled efficacy outcomes, showing an overall objective response rate of 33% with high clinical benefit and notable between-study heterogeneity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cdk46-inhibition-in-the-management-of-metastatic-hrher2-breast-cancer-systematic-review-and-meta-analysis/356388/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cdk46-inhibition-in-the-management-of-metastatic-hrher2-breast-cancer-systematic-review-and-meta-analysis/356388.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the objective of the systematic review and meta-analysis?","Question",{"text":113,"@type":114},"To summarize and synthesize available clinical trial evidence evaluating CDK4/6 inhibitors in metastatic HR+/HER2+ breast cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which patient population and treatment combinations were included?",{"text":118,"@type":114},"Four clinical trials in metastatic HR+/HER2+ breast cancer were included, evaluating CDK4/6 inhibitors combined with endocrine and anti-HER2 therapy.",{"name":120,"@type":111,"acceptedAnswer":121},"What efficacy outcomes were reported in the pooled results?",{"text":122,"@type":114},"The pooled objective response rate was 33%, with complete response at 2%, partial response at 35%, stable disease at 40%, and a clinical benefit rate of 69%.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356388,1790181517,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Targeted Oncology (2026) 21:13–21  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-025-01195-9  \nCDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta‑analysis  \nDaniel Park1 · Marian Varda1 · Sofia Yeremian2 · Andrew Hwang1 · Charity Huang1  \nReceived: 21 September 2025 / Accepted: 30 December 2025 / Published online: 21 January 2026 © The Author(s) 2026  \nAbstract  \nBackground Hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer accounts for approximately 10% of breast cancer cases and is associated with therapeutic resistance and variable clinical outcomes. Preclinical studies suggest that CDK4/6 inhibition may enhance the activity of combined endocrine and HER2-targeted therapy.  \nObjective To summarize and synthesize available clinical trial evidence evaluating CDK4/6 inhibitors in metastatic HR+/ HER2+ breast cancer.  \nPatients and Methods We conducted a systematic review and descriptive meta-analysis of four clinical trials evaluating CDK4/6 inhibitors in combination with endocrine and anti-HER2 therapy in metastatic HR+/HER2+ breast cancer. A random-effects model was used to summarize pooled efficacy outcomes.  \nResults The pooled objective response rate was 33% . Complete response occurred in 2% of patients, partial response in 35%, and stable disease in 40%, and the clinical benefit rate was 69%. Substantial heterogeneity was observed across studies. Conclusions Across available clinical trials, CDK4/6 inhibitor-based combination therapy was associated with disease control in a subset of patients with metastatic HR+/HER2+ breast cancer. Given the heterogeneity of study designs and limited comparative data, these findings should be interpreted cautiously and support the need for further randomized trials to better define optimal treatment strategies and patient selection.  \n* Charity Huang [CHuang2@dhs.lacounty.gov](CHuang2@dhs.lacounty.gov)  \n1 Division of Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA  \n2 University of Nevada-Las Vegas Medical Center, Las Vegas, NV, USA  \n1 Introduction  \nTumors that express human epidermal growth factor receptor 2 (HER2) and hormonal receptors (HR) account for approximately 10% of all breast cancers [1] . HR+/HER2+ breast cancer is an aggressive subtype often associated with central nervous system (CNS) and visceral metastases [2, 3] . The expression of both HER2 and HRs drives resistance mechanisms, with HER2 overexpression conferring intrinsic resistance to hormonal treatment and HR signaling promoting tumor survival despite HER2 blockade [4] . Given the clinical challenges in managing HR+/HER2+ breast cancers, novel therapeutic strategies have been explored, including the use of cyclin-dependent kinase (CDK) 4/6 inhibitors.  \nCDKs drive cell cycle progression, and the concurrent signaling from HR and HER2 leads to increased transcription of the cyclin D1 (CCND1) gene, which further fuels tumor proliferation [5] . Preclinical studies have shown that CDK4/6 inhibition may have synergy with HR and HER2 targeting agents. To date, four clinical trials (two phase II and two phase Ib/II) have evaluated the efficacy of CDK4/6  \ninhibitors in patients with metastatic HR+/HER2+ breast cancer. This meta-analysis synthesizes the available clinical trial data to provide a comprehensive assessment of the efficacy of CDK4/6 inhibition in this patient population.  \n2 Materials and Methods  \n2.1 Literature Search Methods  \nThe Population, Interventions, Comparators, Outcomes, and Study Design (PICOS) framework was utilized to design the search strategy. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to throughout the process. A comprehensive literature search was performed in PubMed/MEDLINE, Embase, and the Cochrane Library from database inception through 28 February 2025.  \nThe PubMed/MEDLINE search strat","cbCaiaT0viuS8S2q","https://ap.wps.com/l/cbCaiaT0viuS8S2q","pdf",1280445,"English","# Abstract\n# 1 Introduction\n# 2 Materials and Methods\n## 2.1 Literature Search Methods\n## 2.2 Data Extraction and Outcome Measures\n## 2.3 Statistical Methods\n# 3 Results\n## 3.1 Eligible Studies and Characteristics","[{\"question\":\"What was the objective of the systematic review and meta-analysis?\",\"answer\":\"To summarize and synthesize available clinical trial evidence evaluating CDK4/6 inhibitors in metastatic HR+/HER2+ breast cancer.\"},{\"question\":\"Which patient population and treatment combinations were included?\",\"answer\":\"Four clinical trials in metastatic HR+/HER2+ breast cancer were included, evaluating CDK4/6 inhibitors combined with endocrine and anti-HER2 therapy.\"},{\"question\":\"What efficacy outcomes were reported in the pooled results?\",\"answer\":\"The pooled objective response rate was 33%, with complete response at 2%, partial response at 35%, stable disease at 40%, and a clinical benefit rate of 69%.\"}]","CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer - Systematic Review and Meta-analysis | PDF",1790125137,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6913912a4ce78e9566aacf96073e8ec9.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07b87b885410332914a8d41171268574.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff035e275fb540901faafc857dde2cdc.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f68fd51c66cacff3392591c9162f370.webp",980,1301]